The B cell in systemic lupus erythaematosus: a rational target for more effective therapy
Identifieur interne : 001961 ( Main/Exploration ); précédent : 001960; suivant : 001962The B cell in systemic lupus erythaematosus: a rational target for more effective therapy
Auteurs : C B Driver [États-Unis] ; M. Ishimori [États-Unis] ; M H Weisman [États-Unis]Source :
- Annals of the Rheumatic Diseases [ 0003-4967 ] ; 2008-10.
English descriptors
- Teeft :
- Abetimus, Abetimus sodium, American college, Animal models, Antibody, Antibody production, Antibody titres, Antimalarial agents, Arthritis, Arthritis rheum, Arthritis rheum leandro, Autoantibody, Autoantibody levels, Autoantibody production, Autoimmune disease, Autoimmune diseases, Baff, Baff costimulation, Baff receptor, Baff receptors, Belimumab, Cell abnormalities, Cell activation, Cell defects, Cell depletion, Cell dysfunction, Cell function, Cell hyperactivity, Cell levels, Cell maturation antigen, Cell migration, Cell numbers, Cell proliferation, Cell receptor, Cell subpopulations, Cell surface molecules, Cell survival, Cell therapy, Cell tolerance, Cell tolerance checkpoints, Clin, Clinical data, Clinical efficacy, Clinical trials, Costimulatory, Costimulatory molecules, Ctla4ig, Curr opin rheumatol looney, Cyclophosphamide, Dendritic cells, Dihydroorotate dehydrogenase, Disease activity, Epratuzumab, Erythaematosus, Erythematosus, Furie, High expression, Humanised antibody, Immunol, Intravenous cyclophosphamide, Investigational therapies, Ligand, Longitudinal analysis, Lupus, Lupus erythematosus, Lupus erythematosus patients, Lupus manifestations, Lupus nephritis, Lymphocyte, Monoclonal antibody, Murine, Murine lupus, Murine lupus nephritis, Mycophenolate mofetil, Nephritis, Other agents, Ovarian failure, Pathogenic antibodies, Peripheral blood, Peripheral blood lymphocytes, Plasma cells, Preliminary results, Rational target, Receptor, Renal, Renal disease, Renal failure, Renal flare, Renal flares, Rheum, Rheumatoid arthritis, Rheumatol, Rheumatology, Rituximab, Rituximab therapy, Serious toxicity, Significant reduction, Systemic, Systemic lupus erythaematosus, Systemic lupus erythematosus, Systemic lupus erythematosus patients, Target organs, Thromboembolic events, Transmembrane activator.
Abstract
Current treatment options for systemic lupus erythaematosus (SLE) are diverse and poorly defined, and aggressive therapy can be associated with serious toxicity and tolerability issues. There is, therefore, a need for new and improved treatments to be studied thoroughly in well-designed controlled trials. B Cell dysfunction has emerged as a key pathophysiological component of SLE and is a prime target for the development of new agents for a wide range of lupus severity, including advanced disease. Although many current drugs appear to modify B cell function, the advent of new, targeted therapies offers the hope of improved efficacy and a better long-term tolerability profile.
Url:
DOI: 10.1136/ard.2007.076745
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001200
- to stream Istex, to step Curation: 001200
- to stream Istex, to step Checkpoint: 000866
- to stream Main, to step Merge: 001969
- to stream Main, to step Curation: 001961
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">The B cell in systemic lupus erythaematosus: a rational target for more effective therapy</title><author><name sortKey="Driver, C B" sort="Driver, C B" uniqKey="Driver C" first="C B" last="Driver">C B Driver</name></author><author><name sortKey="Ishimori, M" sort="Ishimori, M" uniqKey="Ishimori M" first="M" last="Ishimori">M. Ishimori</name></author><author><name sortKey="Weisman, M H" sort="Weisman, M H" uniqKey="Weisman M" first="M H" last="Weisman">M H Weisman</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:ECFC78EBE021338B8A8F536C827BFF4FCD7B5CBE</idno><date when="2008" year="2008">2008</date><idno type="doi">10.1136/ard.2007.076745</idno><idno type="url">https://api.istex.fr/ark:/67375/NVC-1M8N6Z0Q-5/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001200</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001200</idno><idno type="wicri:Area/Istex/Curation">001200</idno><idno type="wicri:Area/Istex/Checkpoint">000866</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000866</idno><idno type="wicri:doubleKey">0003-4967:2008:Driver C:the:b:cell</idno><idno type="wicri:Area/Main/Merge">001969</idno><idno type="wicri:Area/Main/Curation">001961</idno><idno type="wicri:Area/Main/Exploration">001961</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">The B cell in systemic lupus erythaematosus: a rational target for more effective therapy</title><author><name sortKey="Driver, C B" sort="Driver, C B" uniqKey="Driver C" first="C B" last="Driver">C B Driver</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Cedars-Sinai Medical Center, Los Angeles, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Ishimori, M" sort="Ishimori, M" uniqKey="Ishimori M" first="M" last="Ishimori">M. Ishimori</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Cedars-Sinai Medical Center, Los Angeles, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Weisman, M H" sort="Weisman, M H" uniqKey="Weisman M" first="M H" last="Weisman">M H Weisman</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Cedars-Sinai Medical Center, Los Angeles, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Annals of the Rheumatic Diseases</title><title level="j" type="abbrev">Ann Rheum Dis</title><idno type="ISSN">0003-4967</idno><idno type="eISSN">1468-2060</idno><imprint><publisher>BMJ Publishing Group Ltd and European League Against Rheumatism</publisher><date type="published" when="2008-10">2008-10</date><biblScope unit="volume">67</biblScope><biblScope unit="issue">10</biblScope><biblScope unit="page" from="1374">1374</biblScope></imprint><idno type="ISSN">0003-4967</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0003-4967</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Abetimus</term><term>Abetimus sodium</term><term>American college</term><term>Animal models</term><term>Antibody</term><term>Antibody production</term><term>Antibody titres</term><term>Antimalarial agents</term><term>Arthritis</term><term>Arthritis rheum</term><term>Arthritis rheum leandro</term><term>Autoantibody</term><term>Autoantibody levels</term><term>Autoantibody production</term><term>Autoimmune disease</term><term>Autoimmune diseases</term><term>Baff</term><term>Baff costimulation</term><term>Baff receptor</term><term>Baff receptors</term><term>Belimumab</term><term>Cell abnormalities</term><term>Cell activation</term><term>Cell defects</term><term>Cell depletion</term><term>Cell dysfunction</term><term>Cell function</term><term>Cell hyperactivity</term><term>Cell levels</term><term>Cell maturation antigen</term><term>Cell migration</term><term>Cell numbers</term><term>Cell proliferation</term><term>Cell receptor</term><term>Cell subpopulations</term><term>Cell surface molecules</term><term>Cell survival</term><term>Cell therapy</term><term>Cell tolerance</term><term>Cell tolerance checkpoints</term><term>Clin</term><term>Clinical data</term><term>Clinical efficacy</term><term>Clinical trials</term><term>Costimulatory</term><term>Costimulatory molecules</term><term>Ctla4ig</term><term>Curr opin rheumatol looney</term><term>Cyclophosphamide</term><term>Dendritic cells</term><term>Dihydroorotate dehydrogenase</term><term>Disease activity</term><term>Epratuzumab</term><term>Erythaematosus</term><term>Erythematosus</term><term>Furie</term><term>High expression</term><term>Humanised antibody</term><term>Immunol</term><term>Intravenous cyclophosphamide</term><term>Investigational therapies</term><term>Ligand</term><term>Longitudinal analysis</term><term>Lupus</term><term>Lupus erythematosus</term><term>Lupus erythematosus patients</term><term>Lupus manifestations</term><term>Lupus nephritis</term><term>Lymphocyte</term><term>Monoclonal antibody</term><term>Murine</term><term>Murine lupus</term><term>Murine lupus nephritis</term><term>Mycophenolate mofetil</term><term>Nephritis</term><term>Other agents</term><term>Ovarian failure</term><term>Pathogenic antibodies</term><term>Peripheral blood</term><term>Peripheral blood lymphocytes</term><term>Plasma cells</term><term>Preliminary results</term><term>Rational target</term><term>Receptor</term><term>Renal</term><term>Renal disease</term><term>Renal failure</term><term>Renal flare</term><term>Renal flares</term><term>Rheum</term><term>Rheumatoid arthritis</term><term>Rheumatol</term><term>Rheumatology</term><term>Rituximab</term><term>Rituximab therapy</term><term>Serious toxicity</term><term>Significant reduction</term><term>Systemic</term><term>Systemic lupus erythaematosus</term><term>Systemic lupus erythematosus</term><term>Systemic lupus erythematosus patients</term><term>Target organs</term><term>Thromboembolic events</term><term>Transmembrane activator</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Current treatment options for systemic lupus erythaematosus (SLE) are diverse and poorly defined, and aggressive therapy can be associated with serious toxicity and tolerability issues. There is, therefore, a need for new and improved treatments to be studied thoroughly in well-designed controlled trials. B Cell dysfunction has emerged as a key pathophysiological component of SLE and is a prime target for the development of new agents for a wide range of lupus severity, including advanced disease. Although many current drugs appear to modify B cell function, the advent of new, targeted therapies offers the hope of improved efficacy and a better long-term tolerability profile.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Californie</li></region></list><tree><country name="États-Unis"><region name="Californie"><name sortKey="Driver, C B" sort="Driver, C B" uniqKey="Driver C" first="C B" last="Driver">C B Driver</name></region><name sortKey="Ishimori, M" sort="Ishimori, M" uniqKey="Ishimori M" first="M" last="Ishimori">M. Ishimori</name><name sortKey="Weisman, M H" sort="Weisman, M H" uniqKey="Weisman M" first="M H" last="Weisman">M H Weisman</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001961 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001961 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:ECFC78EBE021338B8A8F536C827BFF4FCD7B5CBE
|texte= The B cell in systemic lupus erythaematosus: a rational target for more effective therapy
}}
| This area was generated with Dilib version V0.6.33. |  |